Clinical outcomes in COVID-19 among patients with hypertension in the Philippine CORONA Study

Table 3 Association of having hypertension with the different outcomes of interest

Regression analysis	Adj. OR^a	95% CI	p-value
Severe/critical COVID-19 at nadir	1.57	1.41, 1.75	< 0.001
Neurological presentation/complication	1.54	1.37, 1.73	< 0.001
Full/partial neurological improvement	0.91	0.66, 1.24	0.530
In-hospital mortality	1.33	1.17, 1.52	< 0.001
Respiratory failure	1.99	1.75, 2.28	< 0.001
MV dependence > 5 days	0.49	0.36, 0.68	< 0.001
ICU admission	2.16	1.90, 2.45	< 0.001
ICU stay > 7 days	1.07	0.80, 1.42	0.667
Hospital stay > 14 days	1.06	0.96, 1.17	0.217
Time–to-event analysis	Adj. HR^b	95% CI	p-value
In-hospital mortality	1.13	1.01, 1.26	0.038
Respiratory failure	1.86	1.65, 2.10	< 0.001
ICU admission	1.99	1.76, 2.23	< 0.001

MV mechanical ventilation; ICU intensive care unit; COVID-19 coronavirus disease 2019
^aIndividual univariate multiple logistic regression analysis with independent variable hypertension adjusted for age group, sex, smoking history, diabetes, chronic cardiac disease, chronic kidney disease, chronic respiratory disease, chronic neurologic disease, chronic liver disease, HIV/AIDS, and malignancy
^bIndividual univariate multiple Cox proportional hazards regression analysis with independent variable hypertension adjusted for age group, sex, smoking history, diabetes, chronic cardiac disease, chronic kidney disease, chronic respiratory disease, chronic neurologic disease, chronic liver disease, HIV/AIDS, and malignancy.